Table 2 Retrospective assignment of 589 patients receiving standard therapy on CALGB/Alliance trials to Beat AML genetic treatment groups
From: A precision medicine classification for treatment of acute myeloid leukemia in older patients
Assignment | Performed concurrently | Final assignment | ||
|---|---|---|---|---|
Step 1 | Step 2 | Step 3 | ||
Initial assignment | Initial assignment | Reassignment | ||
Cytogenetics | VAF ≥ 0.3 | VAF ≥ 0.2 | Total number of patients n (%) | |
Core-binding factor | 74 | – | – | 74 (13) |
NPM1m/FLT3-ITD‒ | – | 106 | 1 | 107 (19) |
KMT2A | 13 | – | – | 13 (2) |
IDH2m | – | 56 | 3 | 59 (10) |
IDH1m | – | 33 | 2 | 35 (6) |
TP53m | – | 50 | – | 50 (9) |
Complex karyotype/TP53wt | 28 | – | – | 28 (5) |
FLT3m | – | 96 | 3 | 99 (18) |
TET2m or WT1m | – | 41 | 1 | 42 (7) |
Marker-negative | – | 66 | − 10 | 56 (10) |
Total number of assigned patients per column | 115 | 448 | 10 | 563 |